查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1718351

郁血性心臟衰竭市场：按治疗类型、疾病类型、最终用户和交付方式 - 2025-2030 年全球预测

Congestive Heart Failure Market by Treatment Type, Disease Type, End User, Delivery Methods - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

郁血性心臟衰竭市场在 2024 年的价值为 53.5 亿美元，预计在 2025 年将达到 57.3 亿美元，预计在 2030 年将以 7.41% 的复合年增长率增长，达到 82.2 亿美元。

主要市场统计数据
基准年2024年 53.5亿美元
预计2025年 57.3亿美元
预测年份 2030 82.2亿美元
复合年增长率（%） 7.41%

郁血性心臟衰竭(CHF) 是现代医疗保健中最重大的挑战之一。这种疾病的特征是心臟无法有效地泵血，影响全世界数百万人，并对患者的治疗结果和医疗资源的分配产生重大影响。近年来，诊断和治疗领域都取得了重大进展，激发了临床医生、研究人员和行业相关人员的新兴趣。在当今竞争激烈的环境中，全面的市场研究将揭示 CHF 的临床影响和经济方面。随着临床通讯协定的发展和医疗保健系统旨在降低住院率，对创新诊断工具和有效治疗方法的需求从未如此强烈。

各个领域的相关人员现在比以往任何时候都更加关注改善患者的生活品质、降低发病率和控制医疗成本。本报告透过探索技术突破、不断发展的治疗策略和关键市场细分，深入研究了多方面的 CHF 情况。它还考虑了影响市场动态的更广泛的经济和监管因素，最终为试图驾驭这一复杂领域的决策者提供了至关重要的全面观点。

改变郁血性心臟衰竭

近年来，郁血性心臟衰竭衰竭的治疗方法发生了重大变化，导致医疗保健系统和提供者的治疗策略也发生了重大转变。技术创新和生物医学研究的进步带来了更精确的诊断工具和更有效的治疗方法，使得早期发现和客製化治疗策略越来越可行。这些发展不仅改善了患者的治疗效果，而且还鼓励向基于价值观的医学转变，这种医学优先考虑长期健康促进而不是短期干预。

临床研究为新设备疗法和改进药物疗法的整合铺平了道路。植入式医疗设备和尖端外科手术的重大改进凸显了个人化医疗的广泛趋势。此外，监管机构正在简化突破性治疗方法的核准流程，帮助患者更快获得拯救生命的创新。随着情况的不断发展，市场相关人员被迫采取灵活的策略来跟上这些快速的变化。这种动态环境促进了协作、数据共用和持续创新，共同重新定义了治疗郁血性心臟衰竭的护理标准。

郁血性心臟衰竭的关键细分洞察

郁血性心臟衰竭市场根据几个关键方面进行细分，这些方面提供了对治疗、疾病特征、患者人口统计和治疗方法的深入见解。根据治疗类型的分析可以发现三个不同的领域：设备治疗、药物治疗和手术介入。设备治疗本身又分为心臟再同步治疗、植入式心臟整流去颤器等子类别，而药物治疗又分为血管紧张素转换酶（ACE）抑制剂、醛固酮拮抗剂、血管收缩素Ⅱ受体拮抗剂、 β阻断剂、利尿剂、SGLT2抑制剂等。人们也注意到，外科手术介入包括冠状动脉绕道手术术、心臟瓣膜修復和使用辅助人工心臟。

同时，根据疾病类型，市场分为急性心臟衰竭、慢性心臟衰竭衰竭、左心臟衰竭和右心臟衰竭。左心臟衰竭尤其进一步分为舒张性亚型和收缩性亚型，反映了在患者群体中观察到的微妙的临床表现。基于最终用户的细分进一步区分了医院和诊所，并仔细研究了私人诊所和公立医院以及为心臟科学进步做出贡献的研究机构。最后，给药方法透过将方法分为注射疗法、口服疗法和经皮疗法提供了另一层见解。这些细緻的洞察使相关人员能够更精确地调整他们的临床和商业策略，最终改善患者照护和市场表现。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 随着世界老龄人口不断增长，郁血性心臟衰竭衰竭的盛行率也不断上升
      • 人们对治疗心臟病的微创手术和设备的兴趣日益浓厚。
      • 扩展远端医疗和远端监控解决方案，增加心臟护理的可近性
    • 限制因素
      • 高昂的医疗费用是郁血性心臟衰竭的负担
    • 机会
      • 穿戴式健康技术的创新，用于监测心臟状况并向患者提供即时警报
      • 创造教育平台，提高人们对郁血性心臟衰竭的认识与理解
    • 任务
      • 了解全球核准新型郁血性心臟衰竭药物的复杂法规结构
  • 市场区隔分析
    • 疾病类型：因急性心臟衰竭而需要即时进行医疗干预
    • 最终用户：医院和诊所越来越多地采用稳健、经济高效的解决方案
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章郁血性心臟衰竭（依治疗类型）

  • 装置治疗
    • 心臟再同步治疗
    • 植入式心臟整流去颤器
  • 药物治疗
    • 血管紧张素转换酶抑制剂
    • 醛固酮拮抗剂
    • 血管收缩素II 受体阻断剂
    • β受体阻断剂
    • 利尿剂
    • SGLT2抑制剂
  • 手术介入
    • 冠状动脉绕道手术手术
    • 心臟瓣膜修復
    • 心室辅助装置

第七章郁血性心臟衰竭（依疾病类型）

  • 急性心臟衰竭
  • 慢性心臟衰竭衰竭
  • 左心臟衰竭
    • 舒张性心衰竭
    • 收缩性心臟衰竭衰竭
  • 右心臟衰竭

第 8 章郁血性心臟衰竭（依最终用户）

  • 医院和诊所
    • 私人诊所
    • 公立医院
  • 研究机构

第九章郁血性心臟衰竭以交付方式

  • 注射
  • 口服
  • 经皮

10.美洲郁血性心臟衰竭

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第 11 章亚太地区郁血性心臟衰竭市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12.欧洲、中东和非洲郁血性心臟衰竭

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • ResMed Inc.
  • Sanofi Group
  • Servier Laboratories
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-1A1A064C04DC

The Congestive Heart Failure Market was valued at USD 5.35 billion in 2024 and is projected to grow to USD 5.73 billion in 2025, with a CAGR of 7.41%, reaching USD 8.22 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 5.35 billion
Estimated Year [2025] USD 5.73 billion
Forecast Year [2030] USD 8.22 billion
CAGR (%) 7.41%

Congestive heart failure (CHF) represents one of the most critical challenges in modern healthcare. The condition, characterized by the heart's inability to pump blood efficiently, affects millions worldwide and carries significant implications for patient outcomes and healthcare resource allocation. Recent years have seen notable advancements in both diagnosis and treatment, spurring renewed interest among clinicians, researchers, and industry stakeholders. In today's competitive environment, comprehensive market research offers clarity on both the clinical impact and the economic dimensions of CHF. As clinical protocols evolve and healthcare systems aim to reduce hospitalization rates, the need for innovative diagnostic tools and effective treatment regimens has never been greater.

Stakeholders from various sectors are now more than ever driven by a commitment to improving patient quality of life, reducing morbidity, and managing healthcare costs. This report delves into the multifaceted landscape of CHF by exploring technological breakthroughs, evolving treatment strategies, and key market segmentation. The analysis also considers the broader economic and regulatory factors that influence market dynamics, ultimately providing a well-rounded perspective essential for decision-makers seeking to navigate this complex field.

Transformative Shifts in the Landscape

Recent years have witnessed transformative shifts in the management of congestive heart failure, reshaping the way healthcare systems and providers approach treatment strategies. Technological innovations and advances in biomedical research have yielded more precise diagnostic tools and effective therapies, making early detection and tailored treatment regimes increasingly feasible. These developments are not only enhancing patient outcomes but also driving a shift towards value-based care, where long-term health improvements are prioritized over short-term interventions.

Clinical research has paved the way for the integration of novel device therapies and improved medication regimens. Significant improvements in implantable devices and state-of-the-art surgical procedures underscore a broader trend towards personalized medicine. Moreover, regulatory bodies have streamlined the approval processes for breakthrough treatments, ensuring that life-saving innovations reach patients sooner. As the landscape continues to evolve, market players are compelled to adopt agile strategies that accommodate these rapid changes. This dynamic environment encourages collaboration, data sharing, and continuous innovation, which together are redefining the standard of care in congestive heart failure management.

Key Segmentation Insights in the CHF Market

The market for congestive heart failure is segmented based on several critical dimensions that provide deep insights into treatment, disease characteristics, patient demographics, and delivery methods. An analysis based on treatment type reveals three distinct domains: device therapy, medication, and surgical intervention. Device therapy itself is analyzed further into subcategories such as cardiac resynchronization therapy and implantable cardioverter defibrillators, while the medication category is broken down into ACE inhibitors, aldosterone antagonists, angiotensin II receptor blockers, beta blockers, diuretics, and SGLT2 inhibitors. Surgical interventions also garner attention through procedures like coronary artery bypass grafting, heart valve repair, and the use of ventricular assist devices.

In parallel, focusing on disease type, the market distinguishes between acute heart failure, chronic heart failure, left-sided heart failure, and right-sided heart failure. Notably, left-sided heart failure is further dissected into diastolic and systolic subtypes, reflecting the nuanced clinical presentations observed in patient populations. The segmentation based on the end user further distinguishes between hospitals and clinics, including a closer look at private clinics versus public hospitals, alongside research institutes dedicated to advancing cardiac science. Finally, delivery methods provide another layer of insight by categorizing approaches into injectable, oral, and transdermal therapies. Together, these segmented insights enable stakeholders to tailor clinical and commercial strategies with greater precision, ultimately improving patient care and market performance.

Based on Treatment Type, market is studied across Device Therapy, Medication, and Surgical Intervention. The Device Therapy is further studied across Cardiac Resynchronization Therapy and Implantable Cardioverter Defibrillators. The Medication is further studied across ACE Inhibitors, Aldosterone Antagonists, Angiotensin II Receptor Blockers, Beta Blockers, Diuretics, and SGLT2 Inhibitors. The Surgical Intervention is further studied across Coronary Artery Bypass Grafting, Heart Valve Repair, and Ventricular Assist Devices.

Based on Disease Type, market is studied across Acute Heart Failure, Chronic Heart Failure, Left-Sided Heart Failure, and Right-Sided Heart Failure. The Left-Sided Heart Failure is further studied across Diastolic Heart Failure and Systolic Heart Failure.

Based on End User, market is studied across Hospitals and Clinics and Research Institutes. The Hospitals and Clinics is further studied across Private Clinics and Public Hospitals.

Based on Delivery Methods, market is studied across Injectable, Oral, and Transdermal.

Global Regional Insights Impacting CHF Market Dynamics

Geographical analysis plays a pivotal role in understanding the dynamics impacting the congestive heart failure market. In the Americas, a robust infrastructure and a keen focus on innovative healthcare solutions have been instrumental in driving therapeutic advancements. The region's strong economic fundamentals support extensive clinical trials and swift adoption of breakthrough technologies. In Europe, Middle East & Africa, diverse healthcare landscapes present both opportunities and challenges, as regulatory frameworks and funding structures vary widely. European nations, in particular, are balancing the aging population's demands with significant investments in research and state-of-the-art medical facilities.

Asia-Pacific emerges as a region of rapid growth, bolstered by an increasing middle-class population and expanding healthcare infrastructure. The demand in this region is further accelerated by government initiatives aimed at improving access to advanced medical care and reducing the burden of chronic diseases. Consequently, market players are focusing on region-specific strategies that consider local economic factors, cultural predispositions, and regulatory nuances. Each of these regions offers unique insights into market drivers, providing a comprehensive global perspective essential for informed decision-making across the congestive heart failure spectrum.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Shaping the CHF Market

A closer examination of key players in the congestive heart failure market reveals the pivotal role multinational corporations play in advancing treatment protocols and driving market innovation. Industry leaders such as Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Amgen Inc., AstraZeneca, and Bayer AG are at the forefront of developing novel therapies and medical devices that offer improved performance and greater patient convenience. These companies emphasize cutting-edge research and continual product improvements to address the evolving demands of the CHF patient community.

Further contributions come from organizations like Becton, Dickinson and Company, Biotronik SE & Co. KG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, and Eli Lilly and Company, which have established a strong foothold in both therapeutic and diagnostic segments. Other notable players including F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, and Otsuka Pharmaceutical Co., Ltd. continue to shape the competitive landscape with robust product portfolios and strategic collaborations. The market is further enriched by the contributions of Pfizer Inc., ResMed Inc., Sanofi Group, Servier Laboratories, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd., each of which brings specialized expertise in areas ranging from advanced pharmaceuticals to pioneering device therapies. The combined efforts of these companies not only stimulate innovation but also ensure a competitive and dynamic market environment that benefits both patients and healthcare providers.

The report delves into recent significant developments in the Congestive Heart Failure Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Amgen Inc., AstraZeneca, Bayer AG, Becton, Dickinson and Company, Biotronik SE & Co. KG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., ResMed Inc., Sanofi Group, Servier Laboratories, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Strategic Industry Leaders

Industry leaders are encouraged to continually evaluate and adapt their strategic approaches in response to evolving market dynamics surrounding congestive heart failure. A key recommendation is to integrate advanced data analytics and real-world evidence into decision-making processes, which can significantly improve clinical trial designs and post-market surveillance. Emphasizing collaborations between academic institutions and private entities can foster innovation and accelerate the development of next-generation treatments.

It is also vital for organizations to invest in digital health solutions that enhance remote patient monitoring and ensure timely interventions. Recognizing the diverse needs of different patient segments, companies should implement targeted marketing strategies that acknowledge the nuances of treatment types, disease subtypes, and regional healthcare practices. By aligning product development and market access strategies with these insights, industry leaders can secure a competitive edge in both established and emerging markets.

Conclusion: Summary of Trends and Market Potential

In conclusion, the congestive heart failure market is characterized by rapid innovation and a diverse range of treatment and segmentation strategies. The evolving landscape, driven by technological breakthroughs and personalized treatment approaches, has paved the way for significant improvements in patient care. A deeper understanding of segmentation - spanning treatment types, disease classifications, end user profiles, and delivery methodologies - provides a robust framework for assessing market potential and identifying growth opportunities.

The global perspective, spanning the Americas, Europe, Middle East & Africa, and Asia-Pacific, further enriches this analysis, highlighting regional strengths and unique challenges. With a competitive environment bolstered by the contributions of several key companies, the market is well-positioned for continued expansion. Decision-makers are thus encouraged to leverage these insights to foster innovation, optimize patient outcomes, and drive sustained business growth.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global geriatric population leading to increased prevalence of congestive heart failure
      • 5.1.1.2. Growing preference for minimally invasive procedures and devices in treating heart conditions
      • 5.1.1.3. Expansion of telemedicine and remote monitoring solutions making heart care more accessible
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment posing affordability issues for congestive heart failure patients
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovating wearable health technologies to monitor heart conditions and provide real-time alerts to patients
      • 5.1.3.2. Creating educational platforms to increase awareness and understanding of congestive heart failure
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating the complex regulatory frameworks for new congestive heart failure drug approvals globally
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Rising need for immediate medical intervention for acute heart failure
    • 5.2.2. End User: Increased adoption of robust and cost-effective solutions in hospitals and clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Congestive Heart Failure Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Device Therapy
    • 6.2.1. Cardiac Resynchronization Therapy
    • 6.2.2. Implantable Cardioverter Defibrillators
  • 6.3. Medication
    • 6.3.1. ACE Inhibitors
    • 6.3.2. Aldosterone Antagonists
    • 6.3.3. Angiotensin II Receptor Blockers
    • 6.3.4. Beta Blockers
    • 6.3.5. Diuretics
    • 6.3.6. SGLT2 Inhibitors
  • 6.4. Surgical Intervention
    • 6.4.1. Coronary Artery Bypass Grafting
    • 6.4.2. Heart Valve Repair
    • 6.4.3. Ventricular Assist Devices

7. Congestive Heart Failure Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Acute Heart Failure
  • 7.3. Chronic Heart Failure
  • 7.4. Left-Sided Heart Failure
    • 7.4.1. Diastolic Heart Failure
    • 7.4.2. Systolic Heart Failure
  • 7.5. Right-Sided Heart Failure

8. Congestive Heart Failure Market, by End User

  • 8.1. Introduction
  • 8.2. Hospitals and Clinics
    • 8.2.1. Private Clinics
    • 8.2.2. Public Hospitals
  • 8.3. Research Institutes

9. Congestive Heart Failure Market, by Delivery Methods

  • 9.1. Introduction
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Transdermal

10. Americas Congestive Heart Failure Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Congestive Heart Failure Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Congestive Heart Failure Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. USV launches affordable heart failure medication OnArni to address early onset cases in India
    • 13.3.2. Johnson & Johnson expands cardiovascular portfolio with V-Wave acquisition, focusing on heart failure innovation
    • 13.3.3. Astellas launches DIGITIVA, a digital health solution for enhanced heart failure management and patient empowerment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca
  • 5. Bayer AG
  • 6. Becton, Dickinson and Company
  • 7. Biotronik SE & Co. KG
  • 8. Boehringer Ingelheim International GmbH
  • 9. Boston Scientific Corporation
  • 10. Bristol-Myers Squibb Company
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche AG
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline plc
  • 15. Johnson & Johnson
  • 16. Medtronic plc
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Otsuka Pharmaceutical Co., Ltd.
  • 20. Pfizer Inc.
  • 21. ResMed Inc.
  • 22. Sanofi Group
  • 23. Servier Laboratories
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CONGESTIVE HEART FAILURE MARKET MULTI-CURRENCY
  • FIGURE 2. CONGESTIVE HEART FAILURE MARKET MULTI-LANGUAGE
  • FIGURE 3. CONGESTIVE HEART FAILURE MARKET RESEARCH PROCESS
  • FIGURE 4. CONGESTIVE HEART FAILURE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. CONGESTIVE HEART FAILURE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. CONGESTIVE HEART FAILURE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONGESTIVE HEART FAILURE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONGESTIVE HEART FAILURE MARKET DYNAMICS
  • TABLE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACUTE HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY CONGESTIVE HEART FAILURE MARKET SIZE, BY DELIVERY METHODS, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DEVICE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND CONGESTIVE HEART FAILURE MA